drugset / Trial / NCT04523727

Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease

NCT04523727

Phase 3 Suspended 45 enrolled Keryx Biopharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

This study will be conducted to assess the safety and tolerability of ferric citrate in pediatric participants with hyperphosphatemia related to chronic kidney disease (CKD).

Timeline

Start
2022-06-16
Primary completion
2026-12
Completion
2027-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Ferric Citrate Unknown Oral

Indications